MediBeaconが革新的腎機能モニターの市場化で2240万ドルの投資契約

AsiaNet 61573 （1074）

【セントルイス（米ミズーリ州）2015年8月26日PRN=共同通信JBN】

＊このほど初めて人間での臨床治験を完了した自社開発による光腎機能モニター

自社開発の非侵襲性リアルタイム腎機能監視システムのメーカーで米ミズーリ州セントルイスに本拠を置くMediBeacon（TM）Inc.はこのほどPansend LLC.と契約を結んだと発表した。HC2 Holdings, Inc.（NYSE MKT: HCHC）の完全所有孫会社であるPansendはMediBeaconに段階的な資金提供の形で2240万ドルを提供することに合意した。

MediBeaconのシステムは光学的な皮膚センサーと光の存在下で輝く自社開発の作用薬を組み合わせたもの。これによって、臨床医は患者の腎機能を継続的かつリアルタイムで監視することが可能になる。最近になって、MediBeaconは人間での初期臨床治験を完了した。

Express Scriptsの最高医務責任者でMediBeaconの科学諮問委員会メンバーでもあるスティーブ・ミラー博士は「腎機能の推定が遅延したり不正確だと臨床治療面でも薬剤開発面でも問題を引き起こす。MediBeaconが持つ非侵襲性でリアルタイムの腎機能測定能力は患者ケアの品質および費用面で大きな影響を与えるものだ」と述べた。

HC2の会長、社長、最高経営責任者（CEO）を兼ねるフィリップ・ファルコーネ氏は「現在ある近代医学の奇跡のいくつかは外部からの資金援助がなければ、存在しなかったろう」として次のように述べた。「当社はMediBeacon経営陣を支援し、この常識を覆す技術を医療の現場にもたらすことを楽しみにしている」医学博士のデービッド・プレゼント氏およびPansendのシェリン・エルドゥミアティ・プルメーカー氏がMediBeacon社の取締役会に参加することになった。

MediBeaconは光感受性作用薬で幅広いポートフォリオを所有しており、これらは今後医療革新を起こす可能性を持った新薬候補の基礎になるものだ。現在、MediBeacon技術の胃腸疾患への応用がビル&メリンダ・ゲイツ財団からの資金援助を受け、セントルイスのワシントン大学医学部で共同研究されている。

MediBeaconの最高経営責任者（CEO）スティーブン・J・ハンリー氏は「当社の焦点は臨床医が患者の転帰を改善することを助けることに当てられている」として次のように述べた。「Pansendの投資を得て、当社はそれを現実のものにすることに一歩近づいた」

MediBeaconに投資した企業はJump Capital、St. Louis BioGenerator、Missouri Technology Corporation、Helix Fund、St. Louis Development Corporationを含む。

RM Global Partners LLCがMediBeaconに対して資金調達面の助言をした。

▽MediBeaconについて

MediBeaconは2012年、Mallinckrodtから光学診断・治療プログラムを取得するためにスティーブン・J・ハンリー氏とリチャード・B・ドーショウ博士によって共同設立された。ハンリー氏は以前、Covidien Mallinckrodtのイメージング・ソリューション部門の社長をしており、現在はMediBeaconの最高経営責任者（CEO）である。ドーショウ博士はMallinckrodtで光学診断・治療プログラムを立ち上げ、その後の開発を指揮した人物であり、現在はMediBeaconの最高科学責任者を務めている。同社は光感受性作用薬で多数の特許を保有しており、それらがMediBeaconの技術プラットホームの基盤になっている。MediBeaconについての詳しい情報はウェブサイト（www.medibeacon.com）を参照。

▽HC2 Holdings, Inc.について

HC2 Holdings, Inc.は上場（NYSE MKT: HCHC）された多角経営の持ち株会社で、持続可能な余剰資金を生み出すことのできる魅力的なビジネスを買収、成長させることを狙いとしている。HC2はテレコム／インフラストラクチャー、米国内大規模建設、エネルギー、海中事業、ライフサイエンスに限定されないが、それらを含む幅広い業界で活動する多様な事業会社を所有している。HC2は同社のすべての株主の価値を極大化するため、魅力的な収益と大きなキャッシュ・フローを生み出す機会を狙いにしている。現在、HC2の所有する事業会社の中の最大手は米国における構造用鋼材の製造をリードするSchuff、世界的なオフショア・エンジニアリング企業で海中ケーブル敷設およびメンテナンスに特化したGlobal Marineである。1994年に設立されたHC2は米バージニア州ハーンドンに本拠を置いている。

ソース：MediBeacon Inc.

▽問い合わせ先

Steven J. Hanley

MediBeacon Inc.

Office - +1-314-269-5808

Email - Hanley@medibeacon.com

www.medibeacon.com

▽HC2 Holdings, Inc.問い合わせ先

HC2 Holdings, Inc.

Ashleigh Douglas

ir@hc2.com

MediBeacon(TM) Inc. Enters into Agreement for $22.4 Million Investment to Bring Breakthrough Noninvasive Real-Time Kidney Monitoring to Market

PR61573

ST. LOUIS, Aug. 26, 2015 /PRN=KYODO JBN/ --

-- Proprietary Optical Renal Function Monitor recently completed first human

clinical trials

St. Louis-based MediBeacon(TM) Inc., maker of a proprietary noninvasive

real-time monitoring system for kidney function, announced it has entered into

an agreement with Pansend LLC.  Pansend, an indirect wholly owned subsidiary of

HC2 Holdings, Inc. (NYSE MKT: HCHC), has agreed to provide $22.4 million in

staged financing.

The MediBeacon system uses an optical skin sensor combined with a proprietary

agent that glows in the presence of light. It provides clinicians continuous

real-time monitoring of a patient's kidney function. MediBeacon recently

completed initial human clinical trials.

Dr. Steve Miller, chief medical officer of Express Scripts and member of

MediBeacon's scientific advisory board stated, "Delayed and imprecise estimates

of kidney function are problematic both in clinical practice and in drug

development. MediBeacon's ability to provide noninvasive, real-time kidney

function measurement could profoundly impact both the quality and cost of

patient care."

"Without financial backing, some of the miracles of modern medicine would not

be here today," said Philip Falcone, HC2 Chairman, President and Chief

Executive Officer. "We look forward to supporting MediBeacon management in

bringing this transformational technology into medical practice." David

Present, MD, and Cherine Eldumiati Plumaker of Pansend will join MediBeacon

Inc.'s Board of Directors.

MediBeacon's extensive portfolio of light-activated agents is the foundation

for a pipeline of potential medical innovations. Application of MediBeacon

technology in gastrointestinal disease is being pursued collaboratively at

Washington University School of Medicine in St. Louis with funding from the

Bill & Melinda Gates Foundation.

"Our focus is helping clinicians improve patient outcomes," said Steven J.

Hanley, MediBeacon's CEO. "With Pansend's investment, we're one step closer to

making it a reality."

MediBeacon's investors include Jump Capital, St. Louis BioGenerator, Missouri

Technology Corporation, the Helix Fund, and the St. Louis Development

Corporation.

RM Global Partners LLC advised MediBeacon on the financing.

About MediBeacon Inc.

MediBeacon was cofounded in 2012 by Steven J. Hanley and Dr. Richard B. Dorshow

to acquire the optical diagnostics and therapeutics program from Mallinckrodt.

Mr. Hanley, former President of Covidien Mallinckrodt's Imaging Solutions

business unit, is MediBeacon's CEO. Dr. Dorshow, who established and led

development of the optical diagnostics and therapeutics program at

Mallinckrodt, is MediBeacon's Chief Scientific Officer. The company holds

numerous patents on its light-activated agents, which are the foundation of

MediBeacon's technology platform. Learn more about MediBeacon at

www.medibeacon.com.

About HC2 Holdings, Inc.

HC2 Holdings, Inc. is a publicly traded (NYSE MKT: HCHC), diversified holding

company, which seeks to acquire and grow attractive businesses that generate

sustainable free cash flow. HC2 has a diverse array of operating subsidiaries

across a broad set of industries, including, but not limited to,

telecom/infrastructure, large-scale U.S. construction, energy, subsea services

and life sciences. HC2 seeks opportunities that generate attractive returns and

significant cash flow in order to maximize value for all stakeholders.

Currently, HC2's largest operating subsidiaries are Schuff, a leading

structural steel fabricator in the United States, and Global Marine, a leading

global offshore engineering company focused on subsea cable installation and

maintenance. Founded in 1994, HC2 is headquartered in Herndon, Virginia.

Cautionary Statement Regarding Forward-Looking Statements

Safe Harbor Statement Under the Private Securities Litigation Reform Act of

1995: This release contains, and certain oral statements made by our

representatives from time to time may contain, forward-looking statements.

Generally, forward-looking statements include information describing actions,

events, results, strategies and expectations and are generally identifiable by

use of the words "believes," "expects," "intends," "anticipates," "plans,"

"seeks," "estimates," "projects," "may," "will," "could," "might," or

"continues" or similar expressions. These statements are based on the beliefs

and assumptions of HC2's management and the management of HC2's subsidiaries.

The Company believes these judgments are reasonable, but you should understand

that these statements are not guarantees of performance or results, and the

Company's actual results could differ materially from those expressed in the

forward-looking statements due to a variety of important factors, both positive

and negative, that may be revised or supplemented in subsequent reports on

Forms 10-K, 10-Q and 8-K. Factors that could cause actual results, events and

developments to differ include, without limitation, capital market conditions,

the ability of HC2's subsidiaries to generate sufficient net income and cash

flows to make upstream cash distributions, trading characteristics of the HC2

common stock, the ability of HC2 and its subsidiaries to identify any suitable

future acquisition opportunities, our ability to realize efficiencies, cost

savings, income and margin improvements, growth, economies of scale and other

anticipated benefits of strategic transactions, integrating financial reporting

of acquired or target businesses, completing pending and future acquisitions

and dispositions, litigation and other contingent liabilities, changes in

regulations, taxes and risks that may affect the performance of the operating

subsidiaries of HC2. Additional information concerning these and other factors

can be found in our filings with the Securities and Exchange Commission,

including our most recent Annual Report on Form 10-K, Quarterly Reports on Form

10-Q and Current Reports on Form 8-K.

You should not place undue reliance on forward-looking statements. All

forward-looking statements attributable to the Company or persons acting on its

behalf are expressly qualified in their entirety by the foregoing cautionary

statements. All such statements speak only as of the date made, and the Company

undertakes no obligation to update or revise publicly any forward-looking

statements, whether as a result of new information, future events or otherwise.

SOURCE: MediBeacon Inc.

CONTACT:

Steven J. Hanley

MediBeacon Inc.

Office - +1-314-269-5808

Email - Hanley@medibeacon.com

www.medibeacon.com

For information on HC2 Holdings, Inc., please contact:

HC2 Holdings, Inc.

Ashleigh Douglas

ir@hc2.com